Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K –Mutated Tumor
Authors:
- Carolyn K. McCourtCMCarolyn K. McCourt
- Jacob GrossJGJacob Gross
- Kevin KalinskyKKKevin Kalinsky
- Ping GuanPGPing Guan
- Lisa M. McShaneLMLisa M. McShane
- Peter J. O'DWyerPOPeter J. O'DWyer
- Matthew T. LaheyMLMatthew T. Lahey
- Cayden MaicanCMCayden Maican
- David PattonDPDavid Patton
- Lyndsay N. HarrisLHLyndsay N. Harris
- 1 March 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400614
Abstract
PURPOSE: NCI-MATCH (EAY131) is a precision medicine trial using genomic testing to allocate patients with advanced malignancies to targeted treatments. Arm Y evaluated capivasertib, a pan AKT inhibitor, in patients with an AKT1 E17K –mutated tumor. Here, we report on the translational objectives of the study, a molecular and genomic analysis of specimens to identify potential biomarkers of response or resistance to capivasertib. METHODS: Eligible patients had AKT1 E17K –mutated metastatic tumors that progressed with standard treatment and received capivasertib 480 mg orally twice daily for 4 days on and 3 days off weekly in 28-day cycles. The primary end point was objective response rate (ORR). We performed whole-exome sequencing, RNA sequencing, and gene set and pathway enrichment analysis on 25 pretreatment tissue samples and evaluated findings in responders (complete response [CR], n = 0, and partial response, n = 9) and nonresponders (stable disease, n = 13, and progressive disease, n = 3). RESULTS: The ORR was 28.6% (10 of 35) in the reported primary trial and 36% (9 of 25) in this translational cohort. Mutations in the TP53 gene were more frequent in responders, whereas the PI3K/AKT/mTOR pathway genes TYRO3 , SYNJ1 , and CDIPT were significantly altered in nonresponders. DNA repair, p53, E2F, and Wnt-beta catenin pathways were enriched in the responder group. Unsupervised clustering of gene expression identified five genes, ANKRD30A , SUSD4 , TTC6 , POTEJ , and POTEI , that were significantly higher in responders and lower in nonresponders. In addition, EGFR expression was significantly increased in nonresponders. CONCLUSION: In patients with AKT1 E17K –mutated tumors, capivasertib achieved a clinically significant ORR. TP53 mutations appear to be associated with response, whereas certain additional PI3K/AKT/mTOR pathway mutations and EGFR overexpression appear to be associated with nonresponse to capivasertib. Further investigation of predictive biomarkers is warranted.Keywords
This publication has 61 references indexed in Scilit:
- Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trialBreast Cancer Research and Treatment, 2021
- A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast CancerClinical Breast Cancer, 2021
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated TumorJAMA Oncology, 2021
- Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancerCancer Letters, 2020
- Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate CancerEuropean Urology, 2019
- A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway AlterationsCancer Cell, 2017
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices PipelineCurrent Protocols in Bioinformatics, 2013
- p53 in breast cancer subtypes and new insights into response to chemotherapyThe Breast, 2013
- HspBP1 levels are elevated in breast tumor tissue and inversely related to tumor aggressivenessCell Stress and Chaperones, 2009